Insider Selling: Phreesia, Inc. (NYSE:PHR) COO Sells 10,716 Shares of Stock

Phreesia, Inc. (NYSE:PHR) COO Evan Roberts sold 10,716 shares of Phreesia stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $27.48, for a total value of $294,475.68. Following the completion of the transaction, the chief operating officer now directly owns 764,307 shares in the company, valued at $21,003,156.36. This represents a 1.38 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Evan Roberts also recently made the following trade(s):

• On Tuesday, January 21st, Evan Roberts sold 12,749 shares of Phreesia stock. The stock was sold at an average price of $27.31, for a total transaction of $348,175.19.
• On Wednesday, January 15th, Evan Roberts sold 1,785 shares of Phreesia stock. The shares were sold at an average price of $26.98, for a total transaction of $48,159.30.
• On Wednesday, January 8th, Evan Roberts sold 2,681 shares of Phreesia stock. The stock was sold at an average price of $27.95, for a total transaction of $74,933.95.
• On Monday, January 6th, Evan Roberts sold 2,873 shares of Phreesia stock. The shares were sold at an average price of $26.61, for a total value of $76,450.53.

Phreesia Stock Down 1.7 %

Shares of PHR traded down $0.49 during trading hours on Wednesday, hitting $28.81. 384,950 shares of the company were exchanged, compared to its average volume of 392,842. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. The company has a market cap of $1.67 billion, a PE ratio of -19.60 and a beta of 0.94. The firm’s 50 day moving average is $24.57 and its 200-day moving average is $23.20. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $29.90.

Phreesia (NYSE:PHR) last announced its earnings results on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The firm had revenue of $106.80 million during the quarter, compared to analysts’ expectations of $106.33 million. During the same quarter in the prior year, the business earned ($0.58) earnings per share. The company’s revenue was up 16.6% on a year-over-year basis. On average, equities research analysts forecast that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of PHR. Trust Point Inc. grew its position in shares of Phreesia by 3.5% in the third quarter. Trust Point Inc. now owns 17,887 shares of the company’s stock valued at $408,000 after purchasing an additional 607 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Phreesia by 3.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company’s stock valued at $637,000 after purchasing an additional 905 shares during the period. MetLife Investment Management LLC grew its position in Phreesia by 3.8% in the 3rd quarter. MetLife Investment Management LLC now owns 30,781 shares of the company’s stock worth $701,000 after purchasing an additional 1,120 shares during the last quarter. R Squared Ltd bought a new position in shares of Phreesia during the 4th quarter worth about $30,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Phreesia by 9.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,015 shares of the company’s stock valued at $319,000 after buying an additional 1,258 shares during the last quarter. Institutional investors own 92.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Piper Sandler reissued an “overweight” rating and set a $33.00 price target (up from $31.00) on shares of Phreesia in a research report on Wednesday. Royal Bank of Canada raised shares of Phreesia from a “sector perform” rating to an “outperform” rating and increased their price target for the stock from $24.00 to $32.00 in a research report on Wednesday, January 8th. Citigroup upped their price objective on shares of Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Needham & Company LLC reissued a “buy” rating and set a $29.00 target price on shares of Phreesia in a research note on Friday, January 10th. Finally, Robert W. Baird dropped their price target on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. Thirteen investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $31.15.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.